Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 4/2009

01-08-2009 | Review Article

Nocturnal hemodialysis

Authors: Paramjit Kalirao, Joshua M. Kaplan

Published in: Clinical and Experimental Nephrology | Issue 4/2009

Login to get access

Abstract

With the increasing number of patients with end stage renal disease comes an increasingly urgent need for renal replacement therapy that is both clinically effective and cost effective. This article explores some of the advantages of nocturnal hemodialysis as well as some of the barriers to its use.
Literature
1.
2.
Pierratos A, Ouwendyk M, Francoeur R, Vas S, Raj DS, Ecclestone AM, et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol. 1998;9:859–68.PubMed
3.
Uldall PR, Francoeur R, Ouwendyk M. Simplified nocturnal home hemodialysis. A new approach to renal replacement therapy. J Am Soc Nephrol. 1994;5:42.
4.
Blagg CR. A brief history of home hemodialysis. Adv Renal Replace Ther. 1996;3:99–105.CrossRef
5.
Suri R, Depner TA, et al. Adequacy of quotidian hemodialysis. Am J Kidney Dis. 2003;42:S42–8.CrossRef
6.
7.
8.
United States Renal Data System. Excerpts from USRDS 2005 Annual Data Report. U.S. Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis 2006; 47(Suppl 1):S1.
9.
O’Seaghdha CM, Foley RN. Septicemia, access, cardiovascular disease, and death in dialysis patients. Perit Dial Int. 2005;25(6):534–40.PubMed
10.
Buzello M, Tornig J, Faulhaber J, Ehmke H, et al. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol. 2003;14(2):311–6.CrossRefPubMed
11.
Bro S, Bentzon JF, Falk E, et al. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol. 2003;14(10):2466–74.CrossRefPubMed
12.
Yuen D, Pierratos A, Richardson RMA, Chan CT. The natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients. Nephrol Dial Transplantation. 2006;21:1407–12.CrossRef
13.
Ottonello L, Gnerre P, et al. Leptin as a Uremic Toxin Interferes with Neutrophil chemotaxis. J Am Soc Nephrol. 2004;15:2366–72.CrossRefPubMed
14.
Pierratos A, McFarlane P, Chan CT. Quotidian dialysis–update 2005. Curr Opin Nephrol Hypertens. 2005;14:119–24.CrossRefPubMed
15.
16.
Gotch FA. Is Kt/V urea a satisfactory measure for dosing the newer dialysis regimens? Semin Dial. 2001;14:15–7.CrossRefPubMed
17.
Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–9.CrossRefPubMed
18.
Clark WR, Leypoldt JK, Henderson LW, et al. Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol. 1999;10:601–9.PubMed
19.
Raj DS, Ouwendyk M, Francoeur R, et al. B2-microglobulin kinetics in nocturnal hemodialysis. Nephrol Dial Transplant. 2000;15:58–64.CrossRefPubMed
20.
Mucsi I, Hercz G, Uldall R, et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. 1998;53:1399–404.CrossRefPubMed
21.
Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorous and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607–17.CrossRefPubMed
22.
Pierratos A, Hercz G, Sherrard DJ, et al. Calcium, phosphorous metabolism and bone pathology on long term nocturnal hemodialysis. J Am Soc Nephrol. 2001;12:274. (abstract).
23.
Kim SJ, Goldstein M, Szabo T, et al. Resolution of massive uremic tumoral calcinosis with daily nocturnal home hemodialysis. Am J Kidney Dis. 2003;41:12.CrossRef
24.
Stack AG, Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States AJKD. 2002;40(6):1202–10.PubMed
25.
Yeboah J, Crouse JR, et al. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults. The Cardiovascular Health Study. Circulation. 2004;109:613–9.CrossRef
26.
Ghiadoni L, Cupisti A, et al. Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol. 2004;17:512–9.PubMed
27.
Pannier B, Guerin AP, Marchais SJ, Metivier F, Safar ME, London G. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int. 2000;57:1091–9.CrossRefPubMed
28.
Passauer J, Pitrosch F, et al. Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. JASN. 2005;16:959–65.CrossRefPubMed
29.
Chan CT, Harvey PJ, et al. Short-term blood pressure, noradrenergic and vascular effects of nocturnal home hemodialysis. Hypertension. 2003;42(5):925–31.CrossRefPubMed
30.
Lindsay RM. The London, Ontario, Daily/Nocturnal Hemodialysis Study. Semin Dial. 2004;17(2):85–91.CrossRefPubMed
31.
Culleton BF, Walsh M, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life. JAMA. 2007;298(11):1291–9.CrossRefPubMed
32.
Chan CT, Notarius CF, et al. Improvement in exercise duration and capacity after conversion to nocturnal home haemodialysis. Nephrol Dial Transplant. 2007;22(11):3285–91.CrossRefPubMed
33.
Fong E, Bargman JM, et al. Cross-sectional comparison of quality of life and illness intrusiveness in patients who are treated with nocturnal home hemodialysis versus peritoneal dialysis. Clin J Am Soc Nephrol. 2007;2:1195–200.CrossRefPubMed
34.
Elder SJ, Pisoni RL, et al. Sleep quality predicts quality of life and mortality risk in haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2008;23(3):998–1004.CrossRefPubMed
35.
Kocak H, Ly J, Chan CT. Improvement in open angle glaucoma by nocturnal home haemodialysis. Neph Dialy Transp. 2006;21(9):2647–9.CrossRef
36.
Jassal SV, Devins GM, et al. Improvements in cognition in patients converting from thrice weekly hemodialysis to nocturnal hemodialysis: a longitudinal pilot study. Kidney Int. 2006;70(5):956–62.CrossRefPubMed
37.
Lynn KL, Buttimore J, Wells JE, et al. Long-term survival of arteriovenous fistulas in home hemodialysis patients. Ki dney International. 2004;65:1890–6.CrossRef
38.
McFarlane PA, Pierratos A, Redelmeier DA. Cost savings of home nocturnal versus conventional in-center hemodialysis. Kidney International. 2002;62:2216–22.CrossRefPubMed
39.
Diaz-Buxo JA, Schlaeper C, VanValkenburgh D. Evolution of home hemodialysis monitoring systems. Hemodial Int. 2003;7:353–5.CrossRefPubMed
40.
Heidenheim AP, Leitch R, Kortas C, Lindsay RM. Patient monitoring in the London daily/nocturnal hemodialysis study. Am J Kidney Dis. 2003;42:61–5.CrossRefPubMed
41.
Rodriguez HJ, Domenici R, Diroll A, Goykhman I. Assessment of dry weight by monitoring changes in blood volume during hemodialysis using Crit-Line. Kidney International. 2005;68:854–61.CrossRefPubMed
42.
Jaeger JQ, Mehta RL. Assessment of Dry Weight in Hemodialysis: An Overview. J Am Soc Nephrol. 1999;10:392–403.PubMed
43.
Ayus JC, Mizani MR, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol. 2005;16(9):2778–88.CrossRefPubMed
Metadata
Title
Nocturnal hemodialysis
Authors
Paramjit Kalirao
Joshua M. Kaplan
Publication date
01-08-2009
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2009
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-008-0110-1

Other articles of this Issue 4/2009

Clinical and Experimental Nephrology 4/2009 Go to the issue

Original Article

Does posttransplant anemia at 6 months affect long-term outcome of live-donor kidney transplantation? A single-center experience

Original Article

Ultrasonography as a predictor of overt bleeding after renal biopsy

Original Article

Pathological influence of obesity on renal structural changes in chronic kidney disease

Original Article

Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker

Guidelines

Aliskiren as an antiproteinuric add-on therapy in primary membranous nephropathy

Case Report

Renal allograft tuberculosis: report of three cases and review of literature
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits